Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
about
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingPotential therapeutic targets for neurokinin-1 receptor antagonistsToxicities of the platinum antineoplastic agents.Update and new trends in antiemetic therapy: the continuing need for novel therapies.Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders.Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomitingThe mammalian tachykinin ligand-receptor system: an emerging target for central neurological disordersAprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Pharmacokinetic evaluation of fosaprepitant dimeglumineAprepitant and fosaprepitant: a 10-year review of efficacy and safetyQuality of life in patients receiving treatment for gynecologic malignancies: special considerations for patient care.Chemotherapy-related nausea and vomiting - past reflections, present practice and future management.Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.Antiemetic therapy in cancer: an update.Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.Emerging drugs for chemotherapy-induced emesis.Helping patients discuss CINV management: development of a Patient Charter.Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitantSafety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.Regulation of nausea and vomiting by cannabinoidsSafety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.Short pulse gastric electrical stimulation for cisplatin-induced emesis in dogs.Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics.Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
P2860
Q28258863-DBFB32DF-ECDA-4288-AECB-6889B22C4712Q28262693-32A34723-276D-41BE-A70B-2CFA5F3D8F69Q33357351-17F6C27F-A309-4147-BEA7-0E6238FA711FQ34143667-A2489BCB-7E67-4334-8B8A-B6014F4B48E7Q34190355-1B43B8AA-AE14-48EA-9D0D-455B3C773FF3Q34239808-412BE218-8EE9-4E83-ACA6-37B527BCB79EQ34259043-9CF7D078-DE3B-401C-8C16-893EAFE7CB98Q34450534-D6B6064C-231A-4867-B900-0EB48F76D6E4Q34458672-7E08190D-9695-4691-98F8-AD8AF051D545Q34588516-D6A27962-EEA5-4EC2-9E93-FA8B33FC3FAFQ35163168-D684FF7B-F4B5-4A81-BE64-9EE1D37B6EDEQ35345557-678F930C-AA47-461C-AE2C-08F5E5F6DC23Q35648863-A8081278-897F-4042-BB10-6DAA3F9E2F2CQ35666500-30AB342C-B638-4578-B72B-964E6C7EBF51Q35779340-A747270F-709F-4F60-B6A9-6F44FD17F14AQ35918427-9DE09612-5C4F-48FE-8C51-E3436DB25779Q35962019-85B94B8F-9AF7-4EB5-A56C-9B6C64024FD5Q35964412-617880B8-53CC-443D-8053-DECDDB637343Q36222061-A5AA9306-AE5D-4B71-8B1D-E9A96F1BB421Q36276557-92FD1EAD-216E-490B-806E-0CFFC3943BA6Q36284018-0BB6028F-1AC3-4C59-8C8E-ABCE1A5B819EQ36407422-761B886A-0204-4477-861F-AAC5D5C8C1C6Q36755026-280FA69D-AFFA-4678-B380-5DBFA510C502Q36823546-A01B3449-0BB5-4FF6-8B10-717DE5953451Q36843470-4C31F145-C470-4533-B519-7CD3BE2AA708Q37316977-56F1D61B-3D4A-41B9-9829-85BAB8340619Q37355479-FAB4903A-2C33-4949-B0FD-8FE3087B89BBQ37677897-24A2F317-0B85-46D1-9ADD-6423DB3A52CCQ37822831-797BBA02-F415-48C3-8750-34C60D7A609CQ37854702-345FAFA9-A6BC-4490-9C23-8E6CDE719D0CQ37982438-1DA68138-292C-4172-8CD2-EAD1E32BF91AQ38036613-36F2C941-F31B-4249-99A3-AB7532DE542EQ39270225-B9399007-9186-4D48-8C9E-A4071B0CEE7AQ42551206-E603B1A5-DB25-4B64-B772-4CB20521A2E9Q44571968-3E08467B-69F5-43CC-BE0D-4516B2044478Q44925317-71E31891-C80B-40F7-ACBF-6BCC87E8A3BFQ44973290-35DC0BF0-3A97-4227-97F7-6195CE8861C6Q46954375-9DD584C8-04D8-4C3B-AF30-466E86AA640D
P2860
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Prevention of cisplatin-induce ...... gonists, L-758,298 and MK-869.
@en
Prevention of cisplatin-induce ...... gonists, L-758,298 and MK-869.
@nl
type
label
Prevention of cisplatin-induce ...... gonists, L-758,298 and MK-869.
@en
Prevention of cisplatin-induce ...... gonists, L-758,298 and MK-869.
@nl
prefLabel
Prevention of cisplatin-induce ...... gonists, L-758,298 and MK-869.
@en
Prevention of cisplatin-induce ...... gonists, L-758,298 and MK-869.
@nl
P2093
P2860
P356
P1433
P1476
Prevention of cisplatin-induce ...... gonists, L-758,298 and MK-869.
@en
P2093
Alain Riviere
Alexandra D Carides
August M Garin
Barry J Gertz
Elmer Brestan
Judith K Evans
Krista Eldridge
Marc L A Decramer
Marina De Smet
P2860
P304
P356
10.1002/CNCR.10516
P407
P577
2002-06-01T00:00:00Z